<DOC>
	<DOC>NCT01082406</DOC>
	<brief_summary>This trial is conducted in Europe. The aim of this clinical trial is to compare the metabolism of a blood-clotting drug (recombinant Factor XIII)) produced by two different manufacturers (Novo Nordisk and Avecia) in healthy male volunteers.</brief_summary>
	<brief_title>Comparison of a Blood Clotting Drug (Recombinant Factor XIII) Produced by Two Different Manufacturers in Healthy Male Subjects</brief_title>
	<detailed_description />
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<criteria>Body Mass Index (BMI) between 18.5 and 30 kg/m2 Good general health based on assessment of medical history, physical examination, ECG (electrocardiogram), and clinical laboratory data at screening, as judged by the physician Nonsmokers Known history of thromboembolic event(s) or potential thromboembolic risk as judged by the physician Blood transfusion within 3 months of trial start Positive for hepatitis B or C infection Positive for Human Immunodeficiency Virus (HIV) infection Excessive consumption of a diet deviating from a normal diet as judged by the physician Blood or plasma donation within the last 3 months prior to trial start Subjects with any history of migraine</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>